1. IHH Healthcare
2. Raffles Medical Group (RMG)
3. Biosensors International Group
4. Religare Health Trust
5. TalkMed Group
IHH Healthcare
Key growth markets with operations and investments in our
home markets of Singapore, Malaysia and Turkey.
Key markets of the People's Republic of China, India and Hong Kong; as well as in other markets such as Brunei, Vietnam, United Arab Emirates ("the UAE"), Macedonia and Iraq.
World's second-largest listed healthcare operator by market capitalisation.
On 25 July 2012, IHH's initial public offering ("IPO") became the first ever IPO to be simultaneously listed on the main markets of Bursa Malaysia Securities Berhad ("Bursa Securities") and Singapore Exchange Securities Trading Limited ("the SGX-ST"). Deemed a major step in creating greater cooperation amongst regional bourses, the Group's dual listing was the largest ever IPO for a hospital operator in Asia, the second largest IPO in Asia for 2012 and the third largest IPO in the world for the same year.
Today, IHH's business units operate over 6,000 licensed beds in 37 hospitals as well as medical centres, clinics and ancillary healthcare businesses across ten countries, with over 3,000 new beds in the pipeline to be delivered through new hospital developments and expansion of existing facilities. We employ more than 25,000 people worldwide.
Our "Mount Elizabeth", "Gleneagles", "Pantai" and "Acibadem" brands are among the most prestigious in Asia and Central and Eastern Europe, with a growing presence in the Middle East. Each IHH-invested company is a premium brand operating in an established and growing home market and, in a number of cases, with significant inbound medical tourism growth potential.
http://www.ihhhealthcare.com/index.php
Raffles Medical Group (RMG)
Raffles Medical Group (RMG), (
Chinese: 莱佛士医疗集团) (
SGX:
R01) established in 1976. The group runs a network of clinics, hospitals, surgical centres, speciality units and medical laboratories islandwide.
In 1976, the group's founders, Dr Loo Choon Yong and Dr Alfred Loh opened their first two clinics in Singapore's Central Business District (CBD) with the aim of providing medical services to corporate clients. By 1989, this had grown to five clinics and it was then that the two friends decided to incorporate their clinics into a medical practice group. Expanding after its incorporation, RMG moved into Singapore's HDB heartlands with their first neighbourhood clinic in 1993. More similar clinics soon followed in other estates.
In 1990, RMG tendered and obtained a contract with the Civil Aviation Authority of Singapore to provide medical services to the passengers transiting through Changi International Airport as well as airport workers. This also marked RMG's first 24-hour clinic.
Today, RMG runs a network of 74 multi-disciplinary clinics across Singapore, and four medical centres in Hong Kong and Shanghai. Airport clinics in Singapore’s
Changi International Airport and Hong Kong’s
Chek Lap Kok International Airport are also managed by them.
The Group's flagship hospital is
Raffles Hospital. It is located in Bugis and consists of 20 different specialist centres which provides specialist services such as obstetrics and gynaecology, cardiology, oncology and orthopaedics.
[1]
In 2005, RMG also began offering health financing under its subsidiary
International Medical Insurers (IMI). RMG also has its own consumer healthcare division which develops and distributes a full range of nutraceuticals, supplements, vitamins and medical diagnostic equipment.
RMG uses the Institutional Group Practice Model. Through this model, specialists work as a team to provide patients quality medical services that are integrated, peer reviewed and medically audited.
http://en.wikipedia.org/wiki/Raffles_Medical_Group
Biosensors International Group
Since 1990, we have been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment.
Always seeking to be at the forefront of product innovation, we entered the interventional cardiology market in 2000 with our proprietary coronary stent and accompanying stent delivery system. In the same year, we further expanded our product line to include angioplasty balloons and catheters.
Since that time, Biosensors has rapidly grown to become the world’s fourth largest supplier of cardiac stents, with the BioMatrix™ family of drug-eluting stent and the Axxess™ self-expanding bifurcation stent. Our pioneering work has continued with the development of the BioFreedom drug-coated stent, which received CE Mark approval in January 2013 and is currently available in selected markets.
The BioMatrix Family of drug-eluting stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed specifically for use with stents and patented by Biosensors, together with a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The latest addition to the BioMatrix Family, BioMatrix NeoFlex™, features an enhanced stent delivery system, bringing exceptional performance in complex lesions and challenging anatomies
The Axxess self-expanding dedicated bifurcation stent features the same winning combination of BA9 and biodegradable polymer with a conical shaped nitinol self-expanding stent platform, specifically designed to conform to the shape of the bifurcation anatomy.
BioFreedom features a microstructured abluminal surface, which permits the controlled release of BA9 without the use of a polymer or other carrier.
http://www.biosensors.com/intl/
Religare Health Trust
RHT is the first business trust listed on the SGX-ST with a portfolio comprising healthcare assets in India.
Our investment mandate is principally to invest in medical and healthcare assets in Asia, Australasia and emerging markets in the rest of the world.
The portfolio comprises 12 Clinical Establishments, 4 Greenfield Clinical Establishments and 2 Operating Hospitals. The total value of these assets are approximately S$844 million as at 30 September 2014.
The Trustee-Manger intends to pursue the following strategies in order to meet the key objective:
- Acquisition Growth Strategy
Source for and acquire assets, in accordance with RHT's investment mandate, with the objective of enhancing distributions to Unitholders.
- Development Strategy
Expand RHT's portfolio of medical and healthcare assets and services including through greenfield development projects.
- Active Asset Management and Enhancement Strategy
Implement pro-active measures to enhance the returns from RHT's existing and future portfolio in consultation with the current or prospective operator(s) of the assets.
- Capital and Financial Risk Management Strategy
Employ an appropriate mix of debt and equity in the financing of the acquisition of medical and healthcare assets and asset enhancements. The Trustee-Manager may also from time to time utilise interest rate and currency hedging strategies to manage the risks associated with changes to interest rate and currency fluctuations.
http://www.religarehealthtrust.com/
TalkMed Group
Premier provider of medical oncology and palliative care health care services in Singapore
We are a group of doctors providing tertiary healthcare services in the fields of medical oncology and palliative care to the oncology patients in the private sector in Singapore through PCC. Tertiary healthcare involves specialised care of a high complexity requiring specialised skills, personnel and support services. We have specialists with special interests in breast cancers, head and neck cancers,gastro-intestinal cancers, uro-gynaecological cancers, and haematology malignancies.
Executive Officers
Our Executive Officers as at the date of this Offer Document comprise our Executive Directors, Dr Ang Peng Tiam and Dr Khoo Kei Siong, and our CFO, Mr Quek Hiong How.
Information on the business and working experience, education and professional qualifications, if any, of our CFO are set out below:
Mr Quek Hiong How is our CFO and is responsible for overseeing the finance and accounting functions of our Group. He was the finance director of Boustead Projects Pte Ltd from October 2005 to July 2009, a subsidiary of Boustead Singapore Limited (an SGX-ST Mainboard-listed company) as well as the chief financial officer of Informatics Holdings Ltd (currently known as Informatics Education Ltd.) from October 2003 to September 2005.
Mr Quek was the chief financial officer for Keppel Communications and Transportation Ltd from February 2000 to June 2003. Mr Quek was also the Vice President (Finance and Administration) for the then-Television Corporation of Singapore Pte Ltd from 1993 to 2000.
Mr Quek is a member of the Institute of Singapore Chartered Accountants (formerly known as the Institute of Certified Public Accountants of Singapore) and a fellow of the Association of Chartered and Certified Accountants, United Kingdom.
http://www.talkmed.com.sg/
Posts
